Reason for request
Inclusion
Clinical Benefit
| Substantial |
The actual benefit of TIVICAY in the indication “treatment of Human Immunodeficiency Virus (HIV)-infected adults and adolescents above 12 years of age” is substantial in antiretroviral naïve patients and in experienced patients with prior treatment failure. |
Clinical Added Value
| moderate |
In patients who have no therapeutic options and whose virus is susceptible to dolutegravir :
The Transparency Committee considers that TIVICAY (dolutegravir), in combination with an optimised background regimen, provides a moderate improvement in actual benefit (level III) in terms of immunological and virological efficacy in therapeutic management. |
| minor |
In antiretroviral-naïve or experienced patients whose virus does not have integrase inhibitor (INI) resistance mutations :
The Transparency Committee considers that TIVICAY (dolutegravir) incombination with other antiretrovirals provides a minor improvement in actual benefit (level IV) compared with raltegravir (ISENTRESS) due to having an immunological and virological efficacy that is not inferior to that of raltegravir with a higher genetic barrier to the development of resistance and better ease of use than raltegravir (a single dose versus two daily doses in the case of raltegravir). |
See also
HAS opinions and decisions
05/03/2014
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
d8YXNbHt17vb6NvF
